Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint
Athira Pharma’s stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to meet primary and key secondary endpoints. This significant drop reflects investor concern over the future of the company’s approach to treating neurodegenerative diseases, particularly Alzheimer’s. The trial aimed to demonstrate […]